Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nebuliser Suspension Clear all
Terminated Phase 2 Interventional Results available

Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome

NCT04064684
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Budesonide, Placebo, Nebulizer
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Days to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

NCT01315236
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Liposomal amikacin for inhalation (LAI), placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 5, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound

NCT03829618
View directory record Official record
Conditions
Bronchiectasis Adult, Mediastinal Lymphadenopathy, Pneumonia, Chest--Diseases, Infiltrates, Bronchopulmonary Disease, Cancer, Lung
Interventions
Topical lidocaine, Nebuliser solution, Nebuliser Suspension
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 5, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

NCT00775138
View directory record Official record
Conditions
Bronchiectasis
Interventions
280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

NCT04032834
View directory record Official record
Conditions
Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tempe, Arizona • Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 5, 2026, 10:51 AM EDT
Terminated Not applicable Interventional

Humidity Therapy for Spontaneously Breathing Tracheostomy Patients

NCT02686489
View directory record Official record
Conditions
Respiratory Failure
Interventions
Heated humidification, Cool bland aerosol
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

NCT05037851
View directory record Official record
Conditions
Pulmonary Aspergillosis
Interventions
Opelconazole, Standard of Care
Drug
Lead sponsor
Pulmocide Ltd
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 5, 2026, 10:51 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04535986
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Peoria, Arizona • Tempe, Arizona • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

NCT03421730
View directory record Official record
Conditions
Wheezing, Reactive Airway Disease, Mild Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
4 Years to 8 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 5, 2026, 10:51 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606, Placebo
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Different Modalities in Reducing Airborne Particulate Concentrations During AGP for Health Volunteers

NCT04681599
View directory record Official record
Conditions
Transmission, Patient-Professional
Interventions
Filter, Scavenger face tent
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Not applicable Interventional Results available

A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD

NCT03933462
View directory record Official record
Conditions
COPD
Interventions
InnoSpire Go, Jet Nebulizer
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Clairton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 5, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
77
States / cities
Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 5, 2026, 10:51 AM EDT